Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543712 · ClinicalTrials.gov registry record · Phase 2
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00543712 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 15 participants.
The verdict
NCT00543712, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.
Interventions
- DRUG PRO95780
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-05-31 |
| Est. Completion | 2008-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543712
The ClinicalTrials.gov registry entry for NCT00543712 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRO95780 is the first listed.
NCT00543712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543712 about?
NCT00543712 is a clinical study titled "A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)". This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.
What is the current status of trial NCT00543712?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-05-31. Estimated completion is 2008-05-05.
What interventions are being tested in trial NCT00543712?
The interventions under investigation include: PRO95780 (DRUG).
Who is sponsoring clinical trial NCT00543712?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.